real-world evidence methodology

Novo's Ozempic® (semaglutide) 2 mg associated with lower risk of major adverse cardiovascular events (death, heart attack, an

EASD Evidence Exposes A Hidden Heart‑Risk Gap

Semaglutide 2 mg showed a lower rate of major adverse cardiovascular events than tirzepatide in a real-world cohort of more than 18,000 type 2 diabetes patients, but the advantage hinges on how the analysis matched participants and accounted for hidden biases. Medical Disclaimer: This article is for informational purposes